key: cord-0941461-ux7krbu8
authors: Scalese, Marco; Sposato, Bruno
title: An epidemiological study on COVID-19 should be carried out: with a serological test, a pharyngeal swab or both?
date: 2020-09-29
journal: J Infect Public Health
DOI: 10.1016/j.jiph.2020.09.007
sha: 713009d93eb4281b0e8aed1fea8b21c174175d64
doc_id: 941461
cord_uid: ux7krbu8

nan

(COVID-19) were reported worldwide. In Italy, no epidemiological study has been done yet to verify how many people have been infected. Therefore, the real prevalence and mortality rate are not known. Since several doubts currently persist regarding the virus transmission dynamics, principally concerning the influence of asymptomatic subjects on the virus's spread, this article discusses the necessity of an epidemiological study on COVID-19 to estimate the number of infected people through a probability sample representing the population. Furthermore, the single use of serological tests to evaluate the prevalence of subjects with COVID-19 infection produces a significant reduced sensitivity in detecting these subjects. The authors suggest to combine the serological test and the pharyngeal swab RT-PCR together to improve the reliability of an epidemiological analysis on the spread of COVID-19. A descriptive, analytical, clinical epidemiological research based on a significant statistical sample is necessary to understand the real impact of COVID-19 infection on our country and to have clear indications on which to base the definition of swab and serological testing policies, health practices and protocols, methods of managing economics and social activities. In Italy, no epidemiological study has been done to verify how many people have been infected. We know that to date we have had 246,488 cases with 35,123 deaths, numbers highlighted by pharyngeal swabs RT-PCR performed on subjects suspected of COVID-19 and their close contacts excluding asymptomatic and paucysymptomatic individuals. Therefore, the real prevalence and mortality rate on the entire population are not known in our country yet. Only in Vo'(Padua, Italy), nasopharyngeal swabs from 2,812 subjects were collected, corresponding to 85.9% of the entire Vo' population, a total of 73 individuals were positive and 30 of them (41.1%; 95% CI 29.7-53.2%) who tested positive were asymptomatic [1] . The actual prevalence was 2.6% which would be decreased to 1.5% without asymptomatic cases. In Italy, only people with symptoms have been mainly tested so far, therefore official data greatly underestimate SARS-CoV-2 occurrence in all the population.

Since several doubts currently persist regarding the virus transmission dynamics, principally concerning the influence of asymptomatic subjects on the virus's spread [2] , it would be vital to know their number, especially now that people's mobility restrictions are over. This would let us know the real impact of the virus, control its spread and, at the same time, allow the population to maintain public and economic activities.

We should probably estimate the number of infected people through a probability sample representing the population obtained by randomly selecting people from the municipal civil record list, following a sampling strategy. By carrying out the RT-PCR test in association with serology tests we could estimate quite correctly the prevalence of SARS-CoV-2 in the target population. In fact, the gold standard for COVID-19 diagnosis was nucleic acid testing for SARS-CoV-2 by RT-PCR.

However, false-negative results may occur due to the presence of amplification inhibitors in the sample or insufficient organisms rising from inappropriate collection, transportation, or handling. On the other hand, serological tests could also lead to several cases of false negatives therefore there might be no evidence of their reliability on asymptomatic patients. There are many serological tests and each of them is differently reliable. An analysis of various serological tests has concluded that both IgM and IgG tests' sensitivity ranges between 72.7% and 100%, while specificity varies between 98.7% to 100% [3] . Furthermore, these tests may give false negative responses in COVID-19 infection's early phase. In fact, the seroconversion of specific IgM and IgG antibodies was observed as early as the 4th day after J o u r n a l P r e -p r o o f symptom onset [4] or even after 9 days [5] . This can lead to low sensitivity of serological tests. Actually, in confirmed COVID-19 patients, sensitivity and specificity percentages of IgM to detect disease were 77.3% (51/66) and 100%, while those of IgG were 83.3% (55/66) and 95.0% respectively [4] . In patients with suspected COVID-19, sensitivity and specificity of IgM were 87.5% (21/24) and 100% and those of IgG were 70.8% (17/24) and 96.6% [4] . Therefore, antibodies against SARS-CoV-2 can be detected from mid to late stages of the disease significantly reducing its sensitivity during its early stages. Carrying out the pharyngeal swab RT-PCR and serological tests together could reduce the sensitivity gap of the latter. Other authors agree with the combined use of the two tests since, as already mentioned, viral nucleic acid and antibody concentrations fluctuate in different infection stages. Consequently, using a combination of molecular and serological assays may permit to determine SARS-CoV-2 infection more effectively [6] . In fact, in patients with undetectable RNA in their respiratory tract samples 

This work received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Suppression of COVID-19 outbreak in the municipality of

Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship

Diagnostic performance of COVID-19 serology assays

Antibody Detection and Dynamic Characteristics in Patients with COVID-19

Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland

Molecular and serological assays for SARS-CoV-2: insights from genome and clinical characteristics

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease

The authors declare to have no conflicts of interest, including specific financial interests, relationships and affiliations relevant to the subject of the manuscript.J o u r n a l P r e -p r o o f